ArticleBMC cancer2025
LINC-PINT expression and rs1059698 polymorphism associate with chemoradiotherapy efficacy in Chinese nasopharyngeal carcinoma patients.
Article in BMC cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
backgroundThe identification of predictive biomarkers for nasopharyngeal carcinoma (NPC) treatment response is critical to improving clinical outcomes. Our previous studies demonstrated that the long non-coding RNA (lncRNA) LINC-PINT enhances the radiosensitivity of NPC cells. However, the clinical relevance of functional polymorphisms in LINC-PINT remains unclear.
methodsA total of 199 Chinese NPC patients who received concurrent platinum-based chemoradiotherapy were enrolled. The association between the LINC-PINT rs1059698 polymorphism and short-term treatment efficacy (assessed 3 months post-treatment) was evaluated using multivariate logistic regression. LINC-PINT expression in NPC tissues was quantified by real-time polymerase chain reaction (PCR). A luciferase reporter assay was performed to assess the effect of rs1059698 on miR-646 binding. Eight machines were further employed learning algorithms to construct predictive models for treatment efficacy.
resultsNPC patients with a complete response (CR) showed significantly higher LINC-PINT expression than those with partial response (PR) or progressive disease (PD) (P < 0.05). The rs1059698 CC genotype was significantly associated with an improved treatment response (CR vs. PR + PD, OR = 0.189, 95% CI: 0.042-0.860, P = 0.031). Individuals carrying the CC genotype also exhibited approximately 1.5-fold higher LINC-PINT expression compared to AA genotype carriers (P < 0.001). Functional analysis showed that the A-to-C substitution at rs1059698 disrupted miR-646 binding to LINC-PINT. Additionally, the Gradient Boosting Machine (GBM) model incorporating rs1059698 and clinical variables achieved moderate predictive accuracy (AUC = 0.765 in training and 0.641 in validation).
conclusionsOur findings suggest that the rs1059698 polymorphism were associated with NPC treatment response possibly by influencing the expression of LINC-PINT or altering miRNA-lncRNA interaction. LINC-PINT rs1059698 may serve as a predictive biomarker for chemoradiotherapy efficacy in NPC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.